You can read the full article atYou can read the full article at Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial Due to increased obesity and inactivity rates, type 2 diabetes (T2D) is a complex, multifaceted disease with a rising prevalence rate
Pearce EN, Farwell AP, Braverman LE
Per chi presenta unobesit grave con comorbidit, vale la pena valutare anche quando la chirurgia bariatrica diventa la scelta pi indicata
those prescribed it for obesity were approximately 7 times more likely
Kaku K, Yamada Y, Watada H, Abiko A, Nishida T, Zacho J, Kiyosue A
Thyroid C-cell tumors: Semaglutides boxed warning also states that the drug has caused thyroid C-cell tumors in rodents